Put baltbear, jepro and other of his ID's to 'ignore'. These buy and bashing names offer absolutely to useful information.
On November 4, 2014, the Spanish Agency of Medicines and Health Products (“AEMPS”) authorized BioTime to conduct a randomized, evaluator-blinded, delayed-treatment-controlled study of the effectiveness and safety of Renevia as a resorbable matrix for the delivery of autologous adipose-derived cells to treat subcutaneous facial lipoatrophy defects associated with antiviral therapy for HIV infection. The pivotal study will include a minimum of 56 and up to 92 HIV positive males and females between 18-65 years of age. Subjects will be randomized with half in the treatment group and half in a delayed-treatment cohort, each receiving a single treatment procedure of Renevia™ with autologous adipose cells harvested by liposuction and implanted in the mid-facial region. The primary effectiveness measure will be the comparison of the change in skin thickness between the treatment and delayed treatment groups. A secondary endpoint will be mid-face volume deficit and global aesthetic improvement scores. Patients will be monitored at one, three, and six-month intervals after treatment.
LifeMap alone will draw in 2/3 mil, not bad for a research product that is just starting to gain ground.
The real money starts coming in early next year when the first two cancer diagnostic products hit the market. I'd guess at least 40 million within a 12 month period for the bladder and breast cancer tests.
And a conservative stock price at that time will be at least $20 a share.
Cancer diagnostic results April 22, and stock price should start to move up from there. Bladder and breast diagnostic product will be out on the market, being used in major hospitals as early as late 2015!....and this is but just one of our many products in development. My suggestion is to get in now, while we are still on the ground floor.
No reason for Biotime to partner with big pharma on PanC-DX, it's a simple blood or urine test. Results will be run through Biotimes proprietary database software.
Good point. If AST hESC vaccine has just as good or better results then autogolous version there will be a HUGE spot light on BTX and their hESC ip. Looking forward to the results. Btw when are the first set of initial results due?
This morning I tuned into wnyc 93.9 FM and they had a special on cancer. In the studio was a doctor and patient talkng about immunotherapies. Doc was asked about dendritic stem cell vaccines and he just about waved them off as not being 'strong enough.' I know there are many dendritic vaccines being developed, so I don't know which he was referring to.
I feel confident since we have both adult/autogolous and hESC(off the shelf), both infused with Geron's telomerase as an antigen.
Anyone have any thoughts concerning competing companies. I see NWBO has a dendritic vaccine in the works but it is not hESC nor with telomarse antigens, also NWBO is 18 MIL in debt and out of cash.
LifeMap medical App 2.0 up next. Looking forward to seeing revenue boost from this as well, this will provide wary investors to finally get on board.
In January 2011 Biotime first announced they were to begin on developing a cancer diagnostic product and within days shot up to $10. PanC-DX will at the end of 2015 be completed and ready for market. My guess is that we will be closer to $20 by end of 2015, and that's not even figuring in our worlds first comprehensive genetic medical diagnostic app LifeMapDiscovery being developed.
Makes me wonder what other future endeavors Dr. west will announce as being his next project. My guess is that BTX will have a new SCNT brand of ips cells will set the standard. Dr. West has his name on three SCNT patents that were created in the last few years.
ALAMEDA, Calif.--(BUSINESS WIRE)--Feb. 6, 2015-- BioTime, Inc. (NYSE MKT:BTX) and its subsidiary OncoCyte Corporation today announced that two abstracts, summarizing clinical studies of OncoCyte's PanC-DxTM diagnostic products for bladder and breast cancer, have been accepted for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 in Philadelphia. PanC-DxTM is a class of non-invasive cancer diagnostics based on OncoCyte's proprietary set of cancer markers, which were discovered by company scientists through an analysis of broad gene expression patterns in numerous cancer types. These markers are the subject of multiple pending patent claims filed in numerous countries worldwide and are owned by OncoCyte.
"Solid diagnostic test performance data derived from large prospective clinical studies is crucial for adoption of novel diagnostic tests by clinicians and payers," said Joseph Wagner, PhD, OncoCyte's Chief Executive Officer. "We are excited by the opportunity to present data from clinical trials of the bladder and breast cancer diagnostics that we are developing. These tests are designed to be accurate and less invasive methods to detect and monitor the presence of cancer as compared to current cancer diagnostic procedures."
"The PanC-DxTM clinical data presentations at the upcoming AACR Annual Meeting are the first of multiple, significant milestones that BioTime and its subsidiaries expect to achieve in 2015. These presentations of clinical data reflect our steady progress toward commercializing cancer diagnostic products aimed at addressing large and growing markets," said Dr. Michael D. West, Ph.D., BioTime's
GeneCards Plus includes GeneAnalytics™, a novel gene set analysis tool, GeneALaCart, the GeneCards batch querying application and VarElect the Next Generation Sequencing phenotyper. LifeMap holds the exclusive worldwide license to market GeneCards, MalaCards, GeneAlaCart and VarElect from Yeda Research and Development Company Ltd., the commercial arm of the Weizmann Institute of Science.
“We are thrilled by the opportunity to partner with LifeMap Sciences, the provider of GeneCards, one of the most comprehensive databases of gene information. We think that our iPathwayGuide is a strong addition at the end of any analysis pipeline and a natural fit in the LifeMap suite of tools,” said Dr. Sorin Draghici, President and CEO of Advaita.
ALAMEDA, Calif.--(BUSINESS WIRE)--LifeMap Sciences, Inc. (“LifeMap”), a subsidiary of BioTime, Inc., announced today a partnership agreement with Advaita Corporation, which develops and sells iPathwayGuide, an advanced web-based pathway analysis platform capable of identifying mechanisms of action and potential drug targets directly from gene-expression experiments. Under the agreement, iPathwayGuide will be integrated into LifeMap’s GeneCards®database of human genes, and offered to GeneCards’ large user base of life scientists. “We are excited to introduce iPathwayGuide to our user base and believe that it fits well with our GeneCards Plus tools and our extensive knowledgebase related to genes, pathways, cells and diseases,” stated Yaron Guan-Golan, Chief Marketing Officer of LifeMap Sciences.
In 2014, LifeMap launched its premium platform, GeneCards Plus, a set of tools for biomedical research powered by the Company’s popular integrated knowledgebase and discovery platform. By offering iPathwayGuide, LifeMap is expanding its offering of research tools to provide an advanced and unique tool that is easy to use, easy to interpret, and fits all budgets. Unlike other pathway analysis applications that assume all genes to be independent, iPathwayGuide considers the size, role, and position of each gene on the pathway as it models high-throughput sequencing data. This advanced approach allows users to quickly prioritize targets and pathways, avoiding false positive and false negative results. In addition to its advanced pathway and gene ontology (GO) analysis, iPathwayGuide also offers the ability to identify putative mechanisms that can explain all observed expression changes, as well as identify the miRNAs that can play an important role in the condition under study.
iPathwayGuide Is the premiere gene analytic big data tool and is now part of LifeMap suite. It' will be used to anylize cancer diagnostic results as well as drug testing analysis. Now that GE partnered with us we will be able to use their ESI licensed data. Dr. West is a genius!